



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Product Information

<b>Description:</b>	This anti-IL-33 antibody is a purified, humanized recombinant monoclonal antibody that recognizes human IL-33 (Interleukin-33). This antibody has been tested for neutralization of IL-33 (Interleukin-33) interaction with IL-1RL1 (interleukin 1 receptor like 1 or IL-33R) in a binding assay. This antibody is similar to Tozorakimab.
<b>Background:</b>	IL-33 is a cytokine of the IL-1 family that is released in response to external triggers, such as trauma, allergen exposure and infections. IL-33 can be either in a reduced or oxidized state, which use different signaling pathways. When in its reduced state (IL-33 <sup>red</sup> ) it binds to IL-1RL1 ((interleukin 1 receptor like 1), also named IL-33R or ST2 (receptor serum-stimulated 2). IL-1RL1 exists as both a membrane bound protein or a truncated soluble form. Binding of IL-33 to IL-1RL1 initiates a signaling pathway that involves NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase), and results in release of pro-inflammatory cytokine and chemokines. The soluble form of IL-1RL1 can act as a decoy receptor for IL-33. Dysregulation in the levels of IL-33 is implicated in the pathology of inflammatory and infectious diseases, including COVID-19, COPD (chronic obstructive pulmonary disease) and asthma. The involvement of IL-33 in these diseases has made it a high value therapeutic target, with strategies such as antibodies being developed to inhibit the binding of IL-33 to its receptor. One example is Tozorakimab (MEDI3506), from AstraZeneca, currently being evaluated as treatment for COPD. Further studies on IL-33 and its receptor will likely result in new therapies for IL-33 related disorders.
<b>Species:</b>	Humanized
<b>Isotype:</b>	IgG1
<b>Clonality:</b>	Monoclonal
<b>Concentration:</b>	1.48 mg/ml
<b>Expression System:</b>	HEK293
<b>Purity:</b>	≥90%
<b>Format:</b>	Aqueous buffer solution.
<b>Formulated In:</b>	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
<b>MW:</b>	Heavy chain: 50 kDa + glycans; Light chain: 22.4 kDa
<b>Glycosylation:</b>	This antibody runs at a higher MW by SDS-PAGE due to glycosylation.
<b>Endotoxin:</b>	3.7 EU/mg
<b>Stability:</b>	At least 6 months at -80°C.
<b>Storage:</b>	-80°C
<b>Instructions for Use:</b>	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
<b>Assay Conditions:</b>	This antibody was tested with a method adapted from IL1RL1:IL33 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit (#82856). A serial dilution of Anti-IL-33 Neutralizing Antibody at 1:3 starting with a final concentration of 10 nM was prepared in 1x PP-02 buffer.
<b>Applications:</b>	Useful for studying the binding and neutralization of IL-33 (Interleukin-33) interaction with IL-1RL1 in ELISA and in cellular assays.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



IL1RL1:IL33-Biotin Neutralizing Assay

